Iodine-125 Brachytherapy Prophylaxis after Radiofrequency Ablation Cannot Benefit Patients in High Risk of Locoregional Hepatocellular Carcinoma Recurrence

Abstract This study evaluated if iodine-125 brachytherapy prophylaxis after radiofrequency ablation (RFA) prolongs time to recurrence (TTR) and overall survival (OS) of patients in high risk of locoregional hepatocellular carcinoma (HCC) recurrence. 116 patients with total tumor necrosis after RFA w...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jian-Fei Tu, Ya-Hui Ding, Li Chen, Xi-Hui Ying, Deng-Ke Zhang, Fa-Zong Wu, Zhong-Wei Zhao, Jian-Song Ji, Wang-Gang Zhang, Hai Zou
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/b4b0f42caab1422991ab01580082beb5
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b4b0f42caab1422991ab01580082beb5
record_format	dspace
spelling	oai:doaj.org-article:b4b0f42caab1422991ab01580082beb52021-12-02T16:06:15ZIodine-125 Brachytherapy Prophylaxis after Radiofrequency Ablation Cannot Benefit Patients in High Risk of Locoregional Hepatocellular Carcinoma Recurrence10.1038/s41598-017-03831-52045-2322https://doaj.org/article/b4b0f42caab1422991ab01580082beb52017-06-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-03831-5https://doaj.org/toc/2045-2322Abstract This study evaluated if iodine-125 brachytherapy prophylaxis after radiofrequency ablation (RFA) prolongs time to recurrence (TTR) and overall survival (OS) of patients in high risk of locoregional hepatocellular carcinoma (HCC) recurrence. 116 patients with total tumor necrosis after RFA were divided into iodine-125 brachytherapy prophylaxis treatment group and control group. The primary endpoint was TTR, and secondary endpoints were OS and treatment-related adverse events. There were no significant differences among the baseline characteristics of two subgroups patients. The mean iodine-125 particles were 29.8 (26.59 ± 12.51 mCi) per patient. The mean follow-up was 25 months, and mean TTR of treatment and control groups were 21.7 and 15.9 months (P = 0.733); mean OS of two subgroups were 41.7 and 40.9 months (P = 0.316). There were no significant differences of 1-, 2-, 3-, 4-and 5-years TTR and OS and patients’ immunity pre- and 1 month post-treatment. Extrahepatic metastasis was found to have a statistically significant influence on TTR, and AFP, extrahepatic metastasis were found to have a statistically significant influence on OS by multivariate analysis. There was no major complications and procedure related death. Iodine-125 brachytherapy prophylaxis after RFA can’t improve TTR and OS of HCC patients who were in high risk of locoregional tumor recurrence.Jian-Fei TuYa-Hui DingLi ChenXi-Hui YingDeng-Ke ZhangFa-Zong WuZhong-Wei ZhaoJian-Song JiWang-Gang ZhangHai ZouNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 7, Iss 1, Pp 1-7 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Jian-Fei Tu Ya-Hui Ding Li Chen Xi-Hui Ying Deng-Ke Zhang Fa-Zong Wu Zhong-Wei Zhao Jian-Song Ji Wang-Gang Zhang Hai Zou Iodine-125 Brachytherapy Prophylaxis after Radiofrequency Ablation Cannot Benefit Patients in High Risk of Locoregional Hepatocellular Carcinoma Recurrence
description	Abstract This study evaluated if iodine-125 brachytherapy prophylaxis after radiofrequency ablation (RFA) prolongs time to recurrence (TTR) and overall survival (OS) of patients in high risk of locoregional hepatocellular carcinoma (HCC) recurrence. 116 patients with total tumor necrosis after RFA were divided into iodine-125 brachytherapy prophylaxis treatment group and control group. The primary endpoint was TTR, and secondary endpoints were OS and treatment-related adverse events. There were no significant differences among the baseline characteristics of two subgroups patients. The mean iodine-125 particles were 29.8 (26.59 ± 12.51 mCi) per patient. The mean follow-up was 25 months, and mean TTR of treatment and control groups were 21.7 and 15.9 months (P = 0.733); mean OS of two subgroups were 41.7 and 40.9 months (P = 0.316). There were no significant differences of 1-, 2-, 3-, 4-and 5-years TTR and OS and patients’ immunity pre- and 1 month post-treatment. Extrahepatic metastasis was found to have a statistically significant influence on TTR, and AFP, extrahepatic metastasis were found to have a statistically significant influence on OS by multivariate analysis. There was no major complications and procedure related death. Iodine-125 brachytherapy prophylaxis after RFA can’t improve TTR and OS of HCC patients who were in high risk of locoregional tumor recurrence.
format	article
author	Jian-Fei Tu Ya-Hui Ding Li Chen Xi-Hui Ying Deng-Ke Zhang Fa-Zong Wu Zhong-Wei Zhao Jian-Song Ji Wang-Gang Zhang Hai Zou
author_facet	Jian-Fei Tu Ya-Hui Ding Li Chen Xi-Hui Ying Deng-Ke Zhang Fa-Zong Wu Zhong-Wei Zhao Jian-Song Ji Wang-Gang Zhang Hai Zou
author_sort	Jian-Fei Tu
title	Iodine-125 Brachytherapy Prophylaxis after Radiofrequency Ablation Cannot Benefit Patients in High Risk of Locoregional Hepatocellular Carcinoma Recurrence
title_short	Iodine-125 Brachytherapy Prophylaxis after Radiofrequency Ablation Cannot Benefit Patients in High Risk of Locoregional Hepatocellular Carcinoma Recurrence
title_full	Iodine-125 Brachytherapy Prophylaxis after Radiofrequency Ablation Cannot Benefit Patients in High Risk of Locoregional Hepatocellular Carcinoma Recurrence
title_fullStr	Iodine-125 Brachytherapy Prophylaxis after Radiofrequency Ablation Cannot Benefit Patients in High Risk of Locoregional Hepatocellular Carcinoma Recurrence
title_full_unstemmed	Iodine-125 Brachytherapy Prophylaxis after Radiofrequency Ablation Cannot Benefit Patients in High Risk of Locoregional Hepatocellular Carcinoma Recurrence
title_sort	iodine-125 brachytherapy prophylaxis after radiofrequency ablation cannot benefit patients in high risk of locoregional hepatocellular carcinoma recurrence
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/b4b0f42caab1422991ab01580082beb5
work_keys_str_mv	AT jianfeitu iodine125brachytherapyprophylaxisafterradiofrequencyablationcannotbenefitpatientsinhighriskoflocoregionalhepatocellularcarcinomarecurrence AT yahuiding iodine125brachytherapyprophylaxisafterradiofrequencyablationcannotbenefitpatientsinhighriskoflocoregionalhepatocellularcarcinomarecurrence AT lichen iodine125brachytherapyprophylaxisafterradiofrequencyablationcannotbenefitpatientsinhighriskoflocoregionalhepatocellularcarcinomarecurrence AT xihuiying iodine125brachytherapyprophylaxisafterradiofrequencyablationcannotbenefitpatientsinhighriskoflocoregionalhepatocellularcarcinomarecurrence AT dengkezhang iodine125brachytherapyprophylaxisafterradiofrequencyablationcannotbenefitpatientsinhighriskoflocoregionalhepatocellularcarcinomarecurrence AT fazongwu iodine125brachytherapyprophylaxisafterradiofrequencyablationcannotbenefitpatientsinhighriskoflocoregionalhepatocellularcarcinomarecurrence AT zhongweizhao iodine125brachytherapyprophylaxisafterradiofrequencyablationcannotbenefitpatientsinhighriskoflocoregionalhepatocellularcarcinomarecurrence AT jiansongji iodine125brachytherapyprophylaxisafterradiofrequencyablationcannotbenefitpatientsinhighriskoflocoregionalhepatocellularcarcinomarecurrence AT wanggangzhang iodine125brachytherapyprophylaxisafterradiofrequencyablationcannotbenefitpatientsinhighriskoflocoregionalhepatocellularcarcinomarecurrence AT haizou iodine125brachytherapyprophylaxisafterradiofrequencyablationcannotbenefitpatientsinhighriskoflocoregionalhepatocellularcarcinomarecurrence
_version_	1718385047710466048

Iodine-125 Brachytherapy Prophylaxis after Radiofrequency Ablation Cannot Benefit Patients in High Risk of Locoregional Hepatocellular Carcinoma Recurrence

Ejemplares similares